BIND Biosciences Inc., of Cambridge, Mass., signed a deal with Amgen Inc., of Thousand Oaks, Calif., worth up to $180.5 million. to collaborate on development of a nanotechnology-based therapeutic for solid tumors. Read More
As Wall Street mulled fourth-quarter sales numbers for Regeneron Pharmaceuticals Inc.'s macular degeneration drug Eylea (aflibercept), which beat expectations but disappointed some investors, CEO Leonard Schliefer spoke to the J.P. Morgan Healthcare Conference, outlining the future of the drug as it faces competition on two fronts. Read More
For a healthy pregnancy to have the best chance of surviving, the cells lining the uterus must undergo a short-lived burst of inflammatory activity about five days after ovulation, which must come to a halt 48 hours later, researchers have found. The discovery suggested new ways of treating women who suffer recurrent miscarriages. Read More
For more than a decade now the technologies associated with the regenerative medicine and cell therapy sectors have been hailed as the "future of medicine." Read More
If just 6 percent of diabetes patients who are obese take Orexigen Therapeutics Inc.'s Contrave (naltrexone SR/bupropion SR), the company will reach $1 billion in sales in short order – assuming the FDA grants approval. Given the agency's action this week, company execs have reason to feel confident. Read More
SAN FRANCISCO – Ironwood Pharmaceuticals Inc. played to a packed house Monday afternoon following the luncheon keynote by journalist Bob Woodward at the J.P. Morgan Healthcare Conference. Read More
• Foundation Medicine Inc., of Cambridge, Mass., said it expanded its Series B financing, raising an additional $13.5 million and bringing the total round to $56 million. Read More
• Savient Pharmaceuticals Inc., of Bridgewater, N.J., said the European Commission granted marketing authorization to Krystexxa (pegloticase) for the treatment of severe debilitating chronic tophaceous gout in adults who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom those medications are contraindicated. Read More
• Intercept Pharmaceuticals Inc., of New York, said partner Dainippon Sumitoma Pharma Co. Ltd., of Osaka, Japan, began a Phase II trial of obeticholic acid (OCA) in adult nonalcoholic steatohepatitis. Read More
• Pfizer Inc., of New York, said the European Commission approved expanding the use of pneumococcal conjugate vaccine Prevener 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) to older children and adolescents, ages 6 to 17. Read More
• Baxter International Inc., of Deerfield, Ill., reported pivotal Phase III results showing that routine prophylaxis vs. on-demand treatment of FEIBA NF (anti-inhibitor coagulant complex [nanofiltered and vapor-heated]) in patients with hemophilia A or B reduced median annual bleed rate. Read More
